Drug Profile
BIBT 986
Alternative Names: BIBT-986Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Thrombosis in Europe (IV)
- 09 Aug 2006 Phase-I clinical trials in Thrombosis in Europe (IV)